Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
PCSK9 encodes a proprotein convertase belonging to the proteinase K subfamily of the secretory subtilase family. De plus, nous expédions PCSK9 Kits (72) et PCSK9 Protéines (60) et beaucoup plus de produits pour cette protéine.
Showing 10 out of 155 products:
Human Polyclonal PCSK9 Primary Antibody pour ChIP, IHC (p) - ABIN268772
Cohen, Pertsemlidis, Kotowski, Graham, Garcia, Hobbs: Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. dans Nature genetics 2005
Show all 10 references for 268772
Human Polyclonal PCSK9 Primary Antibody pour EIA, WB - ABIN453778
McNutt, Kwon, Chen, Chen, Horton, Lagace: Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells. dans The Journal of biological chemistry 2009
Show all 3 references for 453778
Human Polyclonal PCSK9 Primary Antibody pour IHC, ELISA - ABIN185371
Lalanne, Lambert, Amar, Chétiveaux, Zaïr, Jarnoux, Ouguerram, Friburg, Seidah, Brewer, Krempf, Costet: Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells. dans Journal of lipid research 2005
Show all 2 references for 185371
Human Polyclonal PCSK9 Primary Antibody pour FACS, IHC (p) - ABIN391505
Shioji, Mannami, Kokubo, Inamoto, Takagi, Goto, Nonogi, Iwai: Genetic variants in PCSK9 affect the cholesterol level in Japanese. dans Journal of human genetics 2004
Show all 2 references for 391505
Human Polyclonal PCSK9 Primary Antibody pour FACS, IHC (p) - ABIN652320
Abifadel, Varret, Rabès, Allard, Ouguerram, Devillers, Cruaud, Benjannet, Wickham, Erlich, Derré, Villéger, Farnier, Beucler, Bruckert, Chambaz, Chanu, Lecerf, Luc, Moulin, Weissenbach, Prat, Krempf et al.: Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. ... dans Nature genetics 2003
Show all 2 references for 652320
Human Polyclonal PCSK9 Primary Antibody pour IF (p), IHC (p) - ABIN761831
Jia, Song, Yang, Ma, Li, Lu, Cao, Zhang, Zhu, Wang, Leng, Cao, Du, Xu: Effects of Tanshinone IIA on the modulation of miR‑33a and the SREBP‑2/Pcsk9 signaling pathway in hyperlipidemic rats. dans Molecular medicine reports 2016
Human Polyclonal PCSK9 Primary Antibody pour EIA, WB - ABIN569616
Kwon, Lagace, McNutt, Horton, Deisenhofer: Molecular basis for LDL receptor recognition by PCSK9. dans Proceedings of the National Academy of Sciences of the United States of America 2008
Use Crispr-Cas (Montrer CSE1L Anticorps) system to introduce nonsense variants into PCSK9 to lower blood cholesterol levels.
PCSK9 decreased in youth participating in an intensive dietary intervention. Change in HOMA-IR was associated with change in PCSK9, independent of weight loss, suggesting an important relationship with insulin (Montrer INS Anticorps) sensitivity.
these studies support that reductions in Lp(a (Montrer APOA Anticorps)) with PCSK9 inhibition are partly due to increased LDLR (Montrer LDLR Anticorps)-mediated uptake. In most situations, Lp(a (Montrer APOA Anticorps)) appears to compete poorly with LDL for LDLR (Montrer LDLR Anticorps) binding and internalization, but when LDLR (Montrer LDLR Anticorps) expression is increased with evolocumab, particularly in the setting of low circulating LDL, Lp(a (Montrer APOA Anticorps)) is reduced.
Plasma levels of proprotein convertase subtilisin/kexin type 9 (PCSK9), apolipoprotein C-III (apoC3 (Montrer APOC3 Anticorps)) and small dense low density lipoprotein cholesterol (sdLDL-C) showed significant interactions with current dyslipidemias, and were predictive in the screening.
Some loss of function variants in PCSK9 are associated with enhanced LDL cholesterol lowering response to statin therapy.
These observations suggest positive feedback interplay between SMC (Montrer DYM Anticorps)-derived PCSK9 and mtDNA damage in the proinflammatory milieu involving mtROS. This interaction results in cellular injury, characterized by apoptosis-a hallmark of atherosclerosis.
PCSK9 level is not associated with systolic or diastolic blood pressure in hypertensives or normotensives, but it positively correlates with carotid intima-media thickness in hypertensives in univariate but not multivariate analyses, and further researches are needed.
results reveal that the tanshinone IIA modulates LDLR (Montrer LDLR Anticorps) level and activity via down-regulation of PCSK9 expression in hepatic cells
This article reviews the functions and regulatory mechanisms of PCSK9. The effects of PCSK9 on the LDL receptor (Montrer LDLR Anticorps), the relationship of this convertase with IDOL (Montrer MYLIP Anticorps), and treatments currently available against hypercholesterolemia are also discussed. [review]
LC n-3 PUFA intake is associated with a lower risk of nonfatal MI in C-allele carriers of PCSK9 rs11206510 (n = 799) but not in non-C-allele carriers (n = 3188).
Use Crispr-Cas (Montrer CTNND1 Anticorps) system to introduce nonsense variants into PCSK9 to lower blood cholesterol levels.
Studied the combination model of a single AAV-PCSK9 injection, high-fat diet, and partial carotid ligation which induces robust atherosclerosis in the flow-disturbed carotid artery within 3 weeks in C57 mice, and results suggest this is a quick and convenient model to study atherosclerosis and mechanisms using any knockout or transgenic mice without having to generate double knockouts.
AdipoR activation by agonists regulated PCSK9 expression and inhibits atherosclerosis in apoE (Montrer APOE Anticorps)(-/-) mice.
Adeno (Montrer ADORA2A Anticorps)-associated virus mediated infection with a mouse PCSK9 gain-of-function mutation is a rapid, easy, and efficient approach for inducing hypercholesterolemia and promoting abdominal aortic aneurysms in C57BL/6 mice infused with angiotensin II.
conditions that cause ER stress regardless of their ability to dysregulate ER Ca(2 (Montrer CA2 Anticorps)+) inhibit PCSK9 secretion, thereby reducing PCSK9-mediated LDLR (Montrer LDLR Anticorps) degradation and promoting LDLR (Montrer LDLR Anticorps)-dependent hepatic cholesterol uptake.
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor (Montrer LDLR Anticorps) Degradation.
PCSK9 increases hepatic lipid and lipoprotein production via apoE (Montrer APOE Anticorps)- and LDLR (Montrer LDLR Anticorps)-dependent mechanisms
Podocyte damage triggers marked inductions in plasma PCSK9, and knockout of Pcsk9 ameliorates dyslipidemia in a mouse model of nephrotic syndrome.
polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating PCSK9.
This gene encodes a proprotein convertase belonging to the proteinase K subfamily of the secretory subtilase family. The encoded protein is synthesized as a soluble zymogen that undergoes autocatalytic intramolecular processing in the endoplasmic reticulum. The protein may function as a proprotein convertase. This protein plays a role in cholesterol homeostasis and may have a role in the differentiation of cortical neurons. Mutations in this gene have been associated with a third form of autosomal dominant familial hypercholesterolemia (HCHOLA3).
proprotein convertase subtilisin/kexin type 9
, convertase subtilisin/kexin type 9 preproprotein
, neural apoptosis regulated convertase 1
, subtilisin/kexin-like protease PC9
, convertase subtilisin
, neural apoptosis-regulated convertase 1
, proprotein convertase 9
, proprotein convertase PC9
, proprotein convertase subtilisin/kexin type 9 preproprotein
, Proprotein convertase 9
, Subtilisin/kexin-like protease PC9